P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL

• Stephen Opat,
• Alessandra Tedeschi,
• Bei Hu,
• Kim Linton,
• Pam Mckay,
• Sophie Leitch,
• Jie Jin,
• Mingyuan Sun,
• Magdalena Sobieraj-Teague,
• Pier Luigi Zinzani,
• Peter Browett,
• Catherine Thieblemont,
• Anna Marina Liberati,
• Emmanuel Bachy,
• Federica Cavallo,
• Régis Costello,
• Sunil Iyengar,
• Roberto Marasca,
• Heidi Mociková,
• Jin Seok Kim,
• Dipti Talaulikar,
• Zhiyu Liang,
• Jianfeng Xu,
• Chris Tankersley,
• Richard Delarue,
• Melannie Co,
• Judith Trotman

Affiliations

Stephen Opat

1 Monash Health and Monash University, Clayton, Australia

Alessandra Tedeschi

2 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Bei Hu

3 Levine Cancer Institute/Atrium Health, Charlotte, United States

Kim Linton

4 Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, United Kingdom

Pam Mckay

5 Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Sophie Leitch

6 North Shore Hospital, Auckland, New Zealand

Jie Jin

7 The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China

Mingyuan Sun

8 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Magdalena Sobieraj-Teague

9 Flinders Medical Centre, Bedford Park, Australia

Pier Luigi Zinzani

10 Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy

Peter Browett

11 Auckland City Hospital, Grafton, New Zealand

Catherine Thieblemont

12 APHP, Hôpital Saint-Louis, Hemato-oncology, Paris University Diderot, Paris, France

Anna Marina Liberati

13 Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy

Emmanuel Bachy

14 Lyon-Sud Hospital, University of Lyon, Hematology Department, Lyon, France

Federica Cavallo

15 University of Torino/AOU Città della Salute e della Scienza di Torino, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, Torino, Italy

Régis Costello

16 Conception University Hospital, Hematology and Cellular Therapy Department, Marseille, France

Sunil Iyengar

17 Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom

Roberto Marasca

18 University of Modena e Reggio Emilia, Modena, Italy

Heidi Mociková

19 University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Department of Clinical Hematology, Prague, Czech Republic

Jin Seok Kim

20 Yonsei University College of Medicine, Division of Hematology, Department of Internal Medicine, Seoul, Korea, Rep. of South

Dipti Talaulikar

21 Australian National University, Canberra, Australia

Zhiyu Liang

22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States

Jianfeng Xu

22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States

Chris Tankersley

22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States

Richard Delarue

22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States

Melannie Co

22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States

Judith Trotman

23 Concord Repatriation General Hospital, University of Sydney, Concord, Australia